Elhini, S.H.; Wahsh, E.A.; Elberry, A.A.; El Ameen, N.F.; Abdelfadil Saedii, A.; Refaie, S.M.; Elsayed, A.A.; Rabea, H.M.
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals 2022, 15, 1516.
https://doi.org/10.3390/ph15121516
AMA Style
Elhini SH, Wahsh EA, Elberry AA, El Ameen NF, Abdelfadil Saedii A, Refaie SM, Elsayed AA, Rabea HM.
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals. 2022; 15(12):1516.
https://doi.org/10.3390/ph15121516
Chicago/Turabian Style
Elhini, Sahar H., Engy A. Wahsh, Ahmed A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, and Hoda M. Rabea.
2022. "The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients" Pharmaceuticals 15, no. 12: 1516.
https://doi.org/10.3390/ph15121516
APA Style
Elhini, S. H., Wahsh, E. A., Elberry, A. A., El Ameen, N. F., Abdelfadil Saedii, A., Refaie, S. M., Elsayed, A. A., & Rabea, H. M.
(2022). The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals, 15(12), 1516.
https://doi.org/10.3390/ph15121516